1. Belykh AE, Dudka VT, Bobyntsev II, Kryukov AA. Rats’ liver morphology in conditions of acute foot-shock stress against the background of delta sleep-inducing peptide injection. Chelovek Ego Zdorov’ie. 2016;(4):59-66. Russian.
2. Vasil’eva EV, Kondrakhin EA, Salimov RM, Kovalev GI. Comparison of Pharmacological Effects of Heptapeptide Selank after Intranasal and Intraperitoneal Administration to BALB/C and C57BL/6 Mice. Eksp. Klin. Farmakol. 2016;79(9):3-11. Russian.
3. Zozulya AA, Neznamov GG, Syunyakov TS, Kast NV, Gabaeva MV, Sokolov OYu, Serebryakova EV, Siranchieva OA, Andryushchenko AV, Telesheva ES, Syunyakov SA, Smulevich АВ, Myasoedov NF, Seredenin SB. Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia. Zh. Nevrol. Psikhiatr. 2008;108(4):38-48. Russian.
4. Zolotarev YuA, Myasoedov NF, Sokolov OYu, Kost NV, Zozulya AA, Vaskovsky BV. Leu-enkephalin generally labeled with tritium in studying the Selank inhibiting effect on the enkephalin-degrading enzymes of human blood plasma. Rus. J. Bioorgan. Chem. 2004;30(3):207-212.
5. Kolomin TA, Shadrina MI, Slominsky PA, Limborska SA, Myasoedov NF. Changes in expression of the genes for chemokines, cytokines, and their receptors in response to Selank and its fragments. Rus. J. Genetics. 2011;47(5):629-631.